Noetik will use its multimodal AI models to identify which patients will most likely benefit from Agenus’s lead ...

FDA Commissioner Martin Makary, MD, shared his vision for a “New FDA”—one that would decide on drug applications much faster, ...

Researchers say using physically patterned surfaces applied to existing device materials would reduce barriers to commercial application.

By designing proteins de novo scientists can more efficiently create novel therapeutics tailored for specific biological ...

An independent jury of experts will evaluate entries based on scientific merit, feasibility, and potential patient impact.

RNA-seq and spatial transcriptomics showed immune cell subsets that drive kidney and lung complications in systemic sclerosis patients.

Eli Lilly has agreed to acquire Verve Therapeutics for up to $1.3 billion in a deal designed to bolster the buyer’s cardiovascular treatment pipeline with Verve’s gene editing therapies, led by ...

Advances are occurring in spectroscopy, reducing the challenges of rapid signal saturation and the need for extensive sample prep.

The AI unicorn's Perturb-seq atlas is publicly available and detects dose-dependent genetic effects to enhance predictive power for drug discovery.

In addition to being faster and less invasive than a traditional tissue biopsy, the blood test is also potentially more accurate.

PRDX6 and GSTP1 identified as promising enzyme targets for neuroblastoma, offering an alternative to retinoic acid differentiation therapy.

Chrysalis partners with life science clients, from early-stage biofirms to pharmaceutical firms, CROs, and other life science ...